Stockreport

Assessing Spyre Therapeutics (SYRE) Valuation After Strong One Year Return And Premium Price To Book Ratio [Yahoo! Finance]

Spyre Therapeutics, Inc.  (SYRE) 
PDF Spyre Therapeutics (SYRE) has drawn attention after recent trading left the stock with a 1-day return showing a 2.5% decline, a 3-month gain of 20.6%, and a 1-year tota [Read more]